149 related articles for article (PubMed ID: 1347516)
1. Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Tsukamoto H; Takeuchi Y; Tokuda Y; Iwasawa M; Yamamoto T; Masuko T; Hashimoto Y; Habu S
Int J Cancer; 1992 Mar; 50(5):800-4. PubMed ID: 1347516
[TBL] [Abstract][Full Text] [Related]
2. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
3. Specific targeting of in vitro-activated human antitumour effector cells using anti-CD3 x anti-c-erbB-2 bispecific antibody.
Tsukamoto H; Nakamura Y; Masuko T; Hashimoto Y; Habu S; Nishimura T
Immunol Cell Biol; 1993 Apr; 71 ( Pt 2)():109-15. PubMed ID: 8098011
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
[TBL] [Abstract][Full Text] [Related]
5. Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.
Nakamura Y; Tokuda Y; Iwasawa M; Tsukamoto H; Kidokoro M; Kobayashi N; Kato S; Mitomi T; Habu S; Nishimura T
Br J Cancer; 1992 Jul; 66(1):20-6. PubMed ID: 1353365
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy.
Ohta S; Tsukamoto H; Watanabe K; Makino K; Kuge S; Hanai N; Habu S; Nishimura T
Immunol Lett; 1995 Jan; 44(1):35-40. PubMed ID: 7721341
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 x anti-c-ErbB-2 bispecific antibody.
Ohmi Y; Shiku H; Nishimura T
Cancer Immunol Immunother; 1999 Nov; 48(8):456-62. PubMed ID: 10550550
[TBL] [Abstract][Full Text] [Related]
8. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
Weil-Hillman G; Schell K; Segal DM; Hank JA; Sosman JA; Sondel PM
J Immunother (1991); 1991 Aug; 10(4):267-77. PubMed ID: 1834166
[TBL] [Abstract][Full Text] [Related]
9. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
10. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
11. [An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].
Nishimura T; Kuge S; Watanabe K; Lee U; Yahata T; Habu S
Hum Cell; 1994 Sep; 7(3):131-7. PubMed ID: 7873496
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-tumor activity of anti-c-erbB-2 x anti-CD3 epsilon bifunctional monoclonal antibody.
Sugiyama Y; Aihara M; Shibamori M; Deguchi K; Imagawa K; Kikuchi M; Momota H; Azuma T; Okada H; Alper O
Jpn J Cancer Res; 1992 Jun; 83(6):563-7. PubMed ID: 1353752
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
14. Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy.
Kuge S; Miura Y; Nakamura Y; Mitomi T; Habu S; Nishimura T
J Immunol; 1995 Feb; 154(4):1777-85. PubMed ID: 7836762
[TBL] [Abstract][Full Text] [Related]
15. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
[TBL] [Abstract][Full Text] [Related]
16. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.
Lamers CH; van de Griend RJ; Braakman E; Ronteltap CP; Bénard J; Stoter G; Gratama JW; Bolhuis RL
Int J Cancer; 1992 Jul; 51(6):973-9. PubMed ID: 1386349
[TBL] [Abstract][Full Text] [Related]
17. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
18. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
19. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
